Esophageal candidiasis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
* Most commonly seen in [[HIV]] patients (AIDS-defining illness) or chronic inhaled glucocorticoid use | * Most commonly seen in [[HIV]] patients with CD4 count < 100 (AIDS-defining illness) or chronic inhaled glucocorticoid use | ||
==Clinical Features<ref name=candida>Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.</ref>== | ==Clinical Features<ref name=candida>Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.</ref>== | ||
| Line 21: | Line 21: | ||
==Management== | ==Management== | ||
* Fluconazole 400mg PO loading dose, followed by 200mg PO Qdaily x 2 weeks | |||
* Itraconazole 200mg PO Qdaily for 2 weeks | |||
** has more nausea side-effects and drug interactions compared to fluconazole | |||
==Disposition== | ==Disposition== | ||
Revision as of 22:53, 9 September 2016
Background
- Most commonly seen in HIV patients with CD4 count < 100 (AIDS-defining illness) or chronic inhaled glucocorticoid use
Clinical Features[1]
- odynophagia
- dysphagia
- retrosternal pain
- nausea/vomiting
Differential Diagnosis
Esophagitis
- Esophageal candidiasis
- Cytomegalovirus esophagitis
- Herpes Simplex esophagitis
- Eosinophilic esophagitis
- Medication-induced esophagitis
Evaluation
- Thick, white, linear esophageal plaques on endoscopy
Management
- Fluconazole 400mg PO loading dose, followed by 200mg PO Qdaily x 2 weeks
- Itraconazole 200mg PO Qdaily for 2 weeks
- has more nausea side-effects and drug interactions compared to fluconazole
Disposition
See Also
External Links
References
- ↑ Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.